HCV Seek, Test and Rapid Treatment for Young PWID (HCV ST&RT)

实验性的：Rapid Treatment with sofosbuvir/velpatasvir (Intervention arm)

The intervention arm receives same-day medical evaluation and treatment for hepatitis C. They receive medical evaluation, laboratory assessment , baseline questionnaire/interview, and distribution of a medication (sofosbuvir/velpatasvir) "starter pack" on the day of enrollment. Participants who are HCV RNA negative are discontinued from the study. Other participants start medications and receive weekly text messages during treatment to record adherence. They have follow up visits for laboratory tests, medication distribution, and counseling for prevention of reinfection. They have HCV testing at end of treatment and 12 weeks post treatment, and at 48 weeks to assess for reinfection. Each study visit will include a brief questionnaire and qualitative interview.

药品：Sofosbuvir and Velpatasvir

Sofosbuvir/velpatasvir (Epclusa) is an FDA-approved treatment for HCV. It is provided in the intervention arm as part of a rapid treatment strategy,

其他名称：

• Epclusa

无干预：Usual Care (Control arm)

Participants in the control arm will be provided facilitated referral to community HCV providers by an on-site care coordinator already facilitating care at the community site. HCV RNA negative participants will be called to inform them of these results, and then discontinued from the study. HCV RNA positive participants will be asked during the semi-structured interviews as at 12, 24, 36 and 48 week if they engaged in HCV treatment to assess whether their HCV referral has been filled, and to record their current HCV treatment status. They will also receive repeat HCV RNA testing at week 12, 24, and 48. Participants that have started treatment will be asked to sign consent for release of medical records pertaining to HCV-related laboratory testing to determine achievement of treatment response.

The proportion of participants who achieve sustained virologic response 12 (SVR12)

The proportion of participants who achieve sustained virologic response defined as an undetectable HCV RNA viral load 12 weeks after the cessation of treatment (SVR12), in the intervention arm compared to the usual care arm by study week 48.

The proportion of participants who initiate treatment for HCV

The proportion of participants who initiate treatment for HCV in the intervention arm compared to the usual care arm by study week 48.

The proportion of participants who complete the prescribed course of treatment for HCV

The proportion of participants who complete the prescribed course of treatment for HCV in the intervention arm compared to the usual care arm by study week 48

The proportion of participants who achieve SVR 12 that have HCV reinfection

The proportion of participants in both arms who achieve SVR 12 that have HCV reinfection by Week 48